Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 + serplulimab in BRAF V600E-mutant advanced non-small cell lung cancer
CTR20222996Phase 2Terminated
- Sponsor
- HyBioPharma
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208, serplulimab in non-small cell lung cancer (NSCLC), sponsored by HyBioPharma. Started Feb 2023; status: terminated.
02
Drugs
HLX208serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222996.